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Abstract 
 
While there is a large and growing international literature on economic aspects of 
biotechnology innovation (for example, work by Carlsson, McKelvey, Orsenigo, 
Zucker and Darby) these studies concentrate on the United States and Europe. The 
New Zealand biotechnology industry may be expected to develop along a different 
trajectory as a consequence of a markedly different set of initial and framework 
conditions. This paper presents the results of an ongoing study that aims to fill some of 
the gaps in our knowledge of innovation processes in New Zealand while using the 
international literature as a benchmark. The size and structure of modern biotech activity 
in New Zealand is described and compared to other OECD countries using biotech 
patent data and results from the New Zealand and Canadian biotechnology surveys. 
The paper then focuses on factors affecting innovation in biotechnology; framework 
conditions, government policy R&D funding and the role of networks and other 
linkages.  
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1. Introduction 
 
Modern biotechnology has the potential to transform large parts of the global economy and to 
have a major impact on the way we live. Its birth is usually traced back to the development of 
the recombinant DNA technique in 1973 and hybridoma technology in 1975 (Orsenigo, 1989, 
p. 37). The rapid pace and widespread impact of developments in biotechnology since that 
time has often been referred to as the biotechnology revolution. There is a large and growing 
international literature on economic aspects of biotechnology innovation which McKelvey 
(2000) has characterised as “an area of research which attempts to explain how and why the 
new techniques and knowledge of modern biotechnology can have economic impacts”. This 
paper describes some of the results of an ongoing study that will describe and analyse the 
innovation system for biotechnology in New Zealand focussing on the major actors and the 
linkages among them. 
 
The first part of this paper outlines a theoretical framework based on the systems of innovation 
literature and reviews some key indicators of the effectiveness of New Zealand’s national 
system of innovation (NIS). The size and competitive position of biotech activity in New 
Zealand is then described based on data from a variety of sources including the recently 
completed biotechnology survey and an analysis of biotech patent data. Part 3 presents and 
analyses data on various factors affecting biotech innovation based on the OECD’s Oslo 
Manual framework. Part 4 draws some conclusions on the state of New Zealand’s innovation 
system for biotechnology. 
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Definition of Biotechnology 
The term biotechnology was coined in 1919 by Karl Ereky, a Hungarian agricultural economist 
to refer to “all the lines of work by which products are produced from raw materials with the 
aid of living organisms”(Bud, 1989, p. 10). Since then “the word biotechnology has been re-
developed at least four times and its definition changed on each occasion” (Kennedy, 1991, p. 
218) and in recent years has become increasingly synonymous with genetic modification (GM). 
For reasons explained above, the economics literature has tended to focus on modern 
biotechnology defined in this paper to include GM and modern biotech processes; namely (1) 
recombinant DNA technology, (2) use of antibodies (3) protein engineering (4) novel 
bioprocessing techniques (Eliasson and Eliasson, 1997, p. 145, U.S. Congress, 1991, p. 5). 
The term “modern” is used to distinguish processes that have been developed in the last 30 
years or so, from traditional biotech areas such as fermentation and extraction. 
The Systems of Innovation Framework 
This study uses the Systems of Innovation (SI) literature (Freeman, 1987, Lundvall, 1992, 
Nelson, 1993) as a theoretical framework. Central to this concept is the idea that the overall 
innovation performance of an economy depends not so much on how specific organisations 
perform but on how well they interact with each other. Systems of innovation have been 
analysed at several levels ranging from sectoral and enterprise specific innovation systems, to 
local, national, regional and global systems of innovation.  
 
Modern biotechnology requires a multi-sectoral approach since it’s techniques are used in a 
number of different “biotechnology-based sectors”(Saviotti, 1998, p. 19) as such, Carlsson 
and Stankiewicz’s notion of a technological system (TS) is perhaps best suited to model the 
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interaction of the various actors. Carlsson recently defined a TS as: "a network of agents 
interacting in a specific technology under a particular institutional infrastructure or set of 
infrastructures and involved in the generation, diffusion, and utilization of technology" (1999, p. 
12). 
 
Bartholomew (1997) was perhaps the first author to refer to a national system of 
biotechnology innovation which she defined as “the specific institutional arrangements within 
a country which affect the generation of scientific knowledge relevant to biotechnology, and the 
diffusion of that knowledge throughout industry”. 
 
Country specific factors in the development of the biotechnology industry have been 
extensively investigated often within a SI framework e.g. in Canada, Japan and Germany 
(Arundel and Rose, 1999, Fransman and Tanaka, 1995, Momma and Sharp, 1999). Less 
work has been published on smaller or less developed economies with the exception of Fontes 
and Novais (1998) on Portugal, Rickne (1999) on Sweden and various authors (Janszen and 
Deganaars, 1998, van Geenhuizen, 1999) on the Netherlands.  
New Zealand’s National System of Innovation 
New Zealanders like to think of themselves as innovative people who can fix anything with a 
piece of No. 8 fencing wire. This kind of innovation enabled many enterprises to develop and 
prosper while making do with local resources but seems to be less suited to competing in the 
global economy. Engelbrecht and Darroch (1999) used a range of indicators to measure 
innovation, knowledge absorption and diffusion and compared the performance of New 
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Zealand with other OECD economies. New Zealand consistently scored below Australia and 
below the average for G7 and other small, high-income OECD countries.  
 
New Zealand had the poorest record of all 18 countries for potential to produce knowledge. 
The high level of FDI inflows and strong imports of manufactured goods mean that there should 
be plenty of opportunities for knowledge to flow into the country. However it had the lowest 
number of science graduates of the 18 sample countries and was ranked lowest on indicators 
of whether diffusion had actually taken place. Overall they concluded that “New Zealand 
continues to have a weak National Innovation System, despite the major changes to its 
research, science and technology sector since the late 1980s, and despite its openness to 
foreign direct investment”. This finding is supported by another empirical investigation into the 
national innovative capacity of a sample of 17 OECD countries from 1973 to 1996, which 
found that “a .. group, including Italy, New Zealand and Spain, lags behind the rest of the 
OECD over the full time period” (Stern et al., 2000, p. 31). 
 
The strength of New Zealand’s science base is an important determinant of the effectiveness of 
the National Innovation System and should also provide a strong indication of the degree (if 
any) of New Zealand’s advantage in the area of biotechnology. Cole and Phelan’s (1999) 
investigation into the scientific productivity of nations found that New Zealand had a high output 
of scientific papers relative to the size of its economy. In a study of 43 countries New Zealand 
ranked seventh ahead of the UK, Canada, Australia the USA and Japan. They then used the 
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number of highly cited papers1 as an indicator for the level of production of scientific 
knowledge. By this measure New Zealand’s science base is slightly below average both 
relative to G7 and to other small developed countries. 
 
Further data on the relative quantity and quality of New Zealand science publishing is available 
from the ISI database for 1994-98 (Institute for Scientific Information, 2000). New Zealand 
authors wrote 0.56% of all 1994-98 science and social science papers on the database. New 
Zealand papers were heavily concentrated in areas such as agricultural, plant and animal 
sciences, geosciences, ecology and environmental sciences. The citation impact of New 
Zealand papers in these areas was within 10% of the world average. 
 
Overall, New Zealand’s science base is relatively small (compared to G7 and small OECD 
countries) and is heavily skewed towards certain areas (e.g. biology, clinical medicine and 
agriculture). New Zealand scientists have a high productivity (measured by papers per 
scientist) but New Zealand science is not highly cited internationally except in a handful of 
specialist areas e.g. pharmacology. 
2. Biotechnology in New Zealand 
 
Despite the small size of its economy and of its science base New Zealand has had a significant 
role in the biotechnology revolution. New Zealand contributed to the birth of modern 
biotechnology through the first description of the structure of DNA by a New Zealand born 
                                                 
1 Based on the number of papers published in 1987 which received 40 or more citations by the Science Citation Index 
between 1987 and 1991. 
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biophysicist, Dr Maurice Wilkins who was later jointly awarded the Nobel Prize with Crick 
and Watson.  
 
Much of New Zealand’s work builds on national strengths in agricultural and primary industry 
production and research. But there are also a number of new enterprises at the forefront of 
research in health and in intellectual property. Recent examples cited by the industry 
organisation BIOTENZ (1998) include: breeding of transgenic crops; clonal afforestation; 
genetic manipulation of flower colour; the world's first enteric bacteria-based bio insecticide; a 
project to map the sheep genome; the world's first sheep genetically engineered for increased 
wool production; and the world's first recombinant livestock vaccine to combat sheep measles. 
 
Most modern biotechnology activities in New Zealand are concentrated in universities and 
Crown Research Institutes (CRI) and a small number of private sector companies e.g. Genesis, 
Probe, ViaLactia. The government has been estimated to spend around NZ$100m a year on 
biotechnology-related research ranging from genomics to processing of natural products 
(Rolleston, 1999, p. 46), of this around NZ$18 million is spent on research involving genetic 
modification (Wright, 2000, p.7). Biotechnology-related research comprises around 17% of 
total spending on ‘the Science Envelope’ (NZ$586 million in 1999/2000, NZ$1 = US$0.42). 
Genesis has invested NZ$41 million in research since its inception in 1994 while CRI’s and 
companies such as Auckland UniServices have also been successful in generating research 
revenue from outside the government sector. Nonetheless it must be recognised that New 
Zealand’s total expenditure on biotechnology research is very small by global standards.  
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Few innovations or processes in modern biotechnology have reached the stage of being 
commercialised. Genesis Research and Development is perhaps one of the closest to achieving 
income from a new biotechnology product; it announced the results of US phase II clinical 
trials of its PVAC Psoriasis treatment in February 2001; one of over 300 biotech products 
now in phase II or phase III trials (Ernst & Young, 1999, p. 35). 
 
In 2000 Statistics New Zealand undertook the first comprehensive survey on the use of 
biotechnology in New Zealand. The main objectives were to describe the present structure of 
the ‘industry’ in order to assist planning and to provide a baseline against which progress could 
be measured at a future date. The survey was sent to 426 enterprises that had been identified 
as possible users of a list of 54 biotechnology processes and achieved a 98% response rate 
with 180 respondents identified as users of at least one process. The high response rate and 
wide ranging methods used to identify possible users of modern biotechnology suggest that the 
survey is likely to have captured almost all significant users of modern biotech over the survey 
period (1998/99). 
 
Respondents were divided into four categories (see Figure 1) based on whether they used 
modern or traditional processes and whether they were creators (engaged in R&D) or simply 
users of biotechnology processes. 
(Figure 1: Classification of Biotech Respondents, about here) 
 
The term Modern Biotech Enterprise (MBE) is used to describe respondents that are engaged 
in R&D into at least one modern biotech process. Academics and policy makers have a 
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particular interest in this group, since their innovative performance will be crucial in determining 
New Zealand’s overall performance in the biotech area. Some of their key characteristics are 
presented as Table 1.  
 
(Table 1: Key Characteristics of Modern Biotech Enterprises, about here) 
 
It may be seen that modern biotechnology R&D was carried out by approximately 57 
enterprises (15 primary product and manufacturing firms, 24 research organisations and 6 
universities) employing  around 1700 people. MBEs were split fairly evenly between the 
private sector (30) and the public sector (27). They reported expenditure on biotech of 
NZ$202 million and income from biotech of NZ$236 million. This compares to MBE income 
from all sources of NZ$2.1 billion i.e. biotech provided around 11% of income for the 57 
MBEs; twelve firms reported that they received all of their income from biotech and so might 
be referred to as dedicated biotech firms. A further 36 enterprises used modern biotech 
processes (but were not engaged in R&D) and employed around 950 people in ‘biotech based 
activities’, which provided income of NZ$112 million. 
 
The Statistics New Zealand biotech survey was closely modelled on work carried out by 
Statistics Canada thus enabling some comparisons to be made. However there are some 
important differences; the New Zealand definition of biotech included several additional 
processes and so was somewhat wider than that used in Canada; the number of biotech firms 
is also not directly comparable since the Canadian survey excluded firms that had less than five 
employees and less than C$100,000 R&D expenditure.  
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An approximate comparison between the two data sets is included as Table 2. It is based on 
application of the Statistics Canada definition of a biotech enterprise to the New Zealand data 
set; namely enterprises which conduct R&D, have a minimum of five employees and biotech 
expenditure of at least NZ$150,000. Data for Australia is also included although based on a 
narrower definition. 
 
(Table 2: Comparison of Biotech in New Zealand, Canada and Australia about here) 
 
New Zealand’s biotech revenue per million population (NZ$54 million) is rather lower than 
Canada's (NZ$94 million), but the difference is fairly small considering Canada’s higher per 
capita income and proximity to the United States. New Zealand has a rather lower mean 
revenue per biotech firm (NZ$5.3m vs. NZ$8.0m); consistent with the predominance of small 
firms in the New Zealand economy. New Zealand appears to have a significantly higher rate of 
biotech employment. There is some evidence that use of biotech processes in New Zealand is 
at an earlier stage with 72% being at the R&D stage against 49% in Canada. 
Data from Patenting 
The use of data from patenting as an indicator of innovative activity has been well established 
for many years. There is also a rapidly increasing literature in the biotechnology area based on 
analysis of patents (Foltz et al., 2000, Joly and de Looze, 1996, Malo and Geuna, 1999, 
McMillan et al., 2000). 
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Analysis of New Zealand patenting activity in biotechnology was carried out using international 
applications published in the Patent Cooperation Treaty (PCT) Electronic Gazette. The PCT 
provides for the filing of an international application to have the same effect as a national 
application in each of the contracted states designated in the application (OECD, 1994, p. 19); 
it thus provides a useful measure of international patenting activity. Use of applications data 
provides a more immediate picture, since it can take up to five years from the first application 
for a patent to be granted.
Methodology based on Engelbrecht and Darroch (1999) was used to compare New 
Zealand’s rate of patenting with G7 and a reference group of small high-income OECD 
countries (see Table 3). For the purposes of this analysis modern biotechnology was taken to 
be synonymous with the International Patent Class C12N, while a ‘Broad Definition’ of 
biotechnology included a number of other classes detailed below2.  
(Table 3: New Zealand and OECD Patenting Rates in Biotechnology, about here) 
 
New Zealand’s rate of modern biotech patent applications at 8 per million of population is 
below the average for the G7 (13.6) and for a reference group of small developed OECD 
economies (15.4); these results are essentially unchanged when the broader definition of 
biotechnology is used. Patent application rates range from a high of 44 for Denmark to a low 
of 1.4 for Italy. Overall New Zealand ranks twelfth out of 18 with a patenting rate slightly 
above that found in France, Germany and Japan. However New Zealand’s performance is 
disappointing compared to other small countries with strong primary industries that it might 
hope to emulate e.g. Denmark (44.1), Netherlands (16.6), Australia (12.1).  
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A breakdown of New Zealand patent applications by organisational type indicates a higher 
rate of patenting by universities and private companies compared to Crown Research 
Institutes. Genesis and it’s partner Fletchers dominate private sector patenting; they were 
responsible for 37% of all PCT applications under patent class C12N. 
3. Factors Affecting Innovation 
 
The OECD’s Oslo Manual (1997, p. 31) lays out a useful framework that allows us to relate 
science investment to all the other factors that may affect innovation.  It describes four 
categories of factors relating to innovation: the framework conditions of national institutional 
and structural factors; the science and engineering base; transfer factors which influence 
linkages and flows of information; and the innovation dynamo of factors shaping innovation at 
the level of the firm. 
 
In other words, science investment is only one of a large number of factors that affect the rate 
of innovation. Even the best managed science investment may have poor outcomes if other 
aspects of the innovation policy terrain are in poor shape e.g. if there is a shortage of 
appropriately trained staff; if the economic climate discourages innovation; or if the network of 
institutions firms and organisations does not have a system of linkages which encourages the 
effective dissemination of results. 
 
                                                                                                                                                
2 Includes A01G, A01H, A01N, C12M, C12N, C12P, C12Q – defined as ‘General Biotechnology’ by Joly and de 
Looze (1996). 
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The title of this paper asks whether New Zealand  has a network of institutions firms and 
organisations - an innovation system for biotechnology. The system, if it exists, is dominated 
by crown research institutes and universities which rely on the government for the majority of 
their funding. Research and teaching in biotechnology is carried out in seven of New Zealand’s 
eight universities. Biotechnology research is also carried out at eight of the country’s nine 
Crown Research Institutes. Indeed this spread of activity has been argued to be a serious 
waste of resources by some who believe that it would be more efficient to concentrate biotech 
research into a smaller number of sites. 
 
Data from interviews with biotech industry representatives carried out as part of this study 
provide little evidence for the existence of a well functioning innovation system for 
biotechnology. Private firms did not place high importance on strong linkages with CRI’s and 
universities.  Universities and CRI’s do not generally have particularly strong linkages; indeed 
the relationship is often more one of competition for scarce research funding. Nor is their much 
movement of staff between CRI’s, universities and the private sector. Turnover at the CRI 
HortResearch was reported to be 3-5% per annum “there were limited cross-CRI transfers 
and just a few people moving on to universities or polytechnics” (Clark et al., 1999, p. 6). 
 
Some private firms placed little emphasis on linkages in development of biotechnology 
innovation; others found few organisations worth linking with (perhaps because the use of 
modern biotechnology in New Zealand is so limited) and so concentrated on developing 
strategic alliances and joint ventures with overseas partners. Others felt that CRI’s and 
universities have little to offer them: “they operate on a completely different time horizon … the 
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difference between commercial reality and university and government research is so wide that 
most people cannot understand that what they are doing never actually achieves a desired 
outcome” (interview C).   
 
This view is supported by another biotech CEO quoted in Mazoyer (1999): “NZ does not 
have a broad range of public research agencies that are well inter-linked. There may not be 
much cross-over into industry – in fact the public research system seems to operate in a sector 
of its own”. Opinion is divided as to whether it is the public research agencies which don’t 
meet the needs of the private sector or the private sector which has a limited ability to apply the 
results of publicly funded R&D or to evaluate opportunities (Winsley et al., 1998, p. 61). It is 
not surprising then, that Mazoyer goes on to conclude that “commercialisation is sometimes 
hindered by a lack of interaction between the science sector and manufacturers … [and that] 
more effective learning interactions and networking between scientists, public and private 
investors and users need to be encouraged” (1999, pp. 6-7). 
 
Modern biotechnology activity in New Zealand may perhaps be better described through the 
idea of ‘islands of excellence’. Leading edge work is carried out in a number of areas; but 
these islands of excellence tend to collaborate strongly with a small number of other 
organisations rather than being strongly connected to any wider innovation system. A good 
example is provided by the forestry industry where a small number of leading companies 
collaborated with the Forest Research Institute to promote research into forest biotechnology. 
A New Zealand company was able to develop the ability to genetically transform pine trees 
using a company scientist, a recent graduate with an MSc in biotechnology and email contact 
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with a colleague in Canada (interview D). This is now an area where New Zealand based firms 
and scientists are at the forefront of technology. Arborgen the world’s leading forestry 
biotechnology company is a joint venture between two huge US companies (International 
Paper and Westvaco Corporation) and three New Zealand companies (Fletcher Challenge 
Forests, Genesis and Carter Holt Harvey).  
 
Similarly Genesis was founded using intellectual property from the University of Auckland and 
has strong partnerships with two CRI's, the New Zealand Dairy Board and six overseas 
companies. However Genesis can probably be best characterised as being part of the 
international innovation system for biotechnology rather than having particularly strong links 
with many New Zealand based institutions. 
Framework Conditions for Innovation 
Many of those interviewed for this study had serious concerns about New Zealand’s 
framework conditions for innovation. They focussed particularly on “the lack of a pro-business 
environment, national attitudes to entrepreneurs and risk takers and the regulatory framework 
which has made New Zealand an expensive country in which to do business”. One interviewee 
cited the recent increase in the top rate of income tax as an example of negative attitudes to 
business that has harmed their ability to recruit scientists internationally. He also expressed the 
opinion that “we don’t like people being enterprising, we don’t admire people being rich 
[and]… if we don’t have an admiration for people taking risks and being successful then we 
won’t have innovation in biotechnology. 
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Increasing levels of popular concern over the safety of some modern biotechnologies 
culminated in the setting up of the Royal Commission on Genetic Modification to inquire “into 
and report on the strategic options available to enable New Zealand to address genetic 
information now and in the future” (Royal Society of New Zealand, 2000). The Commission 
spent over NZ$6 million and 14 months listening to all sides of the debate before concluding 
“that New Zealand should keep its options open. It would be unwise to turn our back on the 
potential advantages on offer, but we should proceed carefully, minimising and managing risks” 
(Royal Commission on Genetic Modification, 2001, p. 2). In October 2001 the government 
announced its response to the Royal Commission report, including permission for field trials to 
restart and a two-year ban on commercial release of genetically modified products.  
 
Work on genetically modified and new organisms in New Zealand is controlled by the 
Hazardous Substances and New Organisms (HSNO) Act 1996 which aims to “protect the 
environment, and the health and safety of people and communities, by preventing or managing 
the adverse effects of hazardous substances and new organisms” (Environmental Risk 
Management Authority, 1999). Serious concerns have been expressed both about the degree 
of control and the associated delays: “it can take 18 months to get approval from ERMA to do 
a piece of research … by the time you get approval to do it, it is a whole new world, 
literally”(interview A). The University of Otago recently fell foul of ERMA regulations on “a 
very low risk project that in any other country would not require the approval of a regulatory 
authority” (Cassie, 2000). There are concerns that implementation of recommendations from 
the Royal Commission will make New Zealand’s regulatory regime even tighter. 
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On the positive side, research costs are estimated to be 40% below international levels (New 
Zealand Trade Development Board, 2000, p. 4). This and New Zealand’s rigorous border 
controls and relatively disease free status have been pushed heavily by BIOTENZ and the 
New Zealand Trade Development Board in an attempt to increase overseas funding of 
biotechnology activities in New Zealand.  
 
Unfortunately these low research costs are a double-edged sword when it comes to attracting 
overseas talent and retaining top New Zealand scientists as illustrated by the following quote 
from a CRI manager: “We were recruiting a plant breeder. We had a very good candidate 
from the US who we brought out here. We paid for him to come out. We said we don’t want 
you to come just for an interview, come for a week. You need to find out about us and we 
need to find out about you. He was our preferred candidate. We offered him between $5,000 
- $10,000 more per annum starting salary. So we really wanted this person. But he converted 
his dollars back and said ‘No’” (Clark et al., 1999, p. 5). 
Government Policy 
Over the six years from 1984 to 1991 New Zealand engaged in “one of the most radical 
market liberalisation programmes initiated anywhere in the world” (Massey, 1995, p. xii), 
“transforming New Zealand from the most to the least regulated economy in the OECD” 
(Hazeldine, 1998, p. 1). These non-interventionist, free market policies continued to dominate 
the New Zealand political scene until the election of a new Labour government in 1999. There 
have been neither large-scale policy interventions designed to increase R&D spending nor 
major funding initiatives to promote biotechnology. Indeed government and industry only seem 
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to have started taking a close interest in biotechnology in the last four to five years (interview 
F).  
 
The present government is taking a more interventionist approach to science policy. As part of 
the most recent round of policy adjustments New Zealand’s Foundation for Research, Science 
and Technology (FRST) has developed a series of Strategic Portfolio Outlines (SPO’s), which 
will guide its investments. Investment in biotechnology falls under the Advanced Biological 
Enterprises SPO which aims to: “generate wealth for New Zealand by assisting the migration of 
the country’s economy into new and emerging markets. To do so, this the SPO will seek to 
develop a coordinated and focused approach to establishing a vibrant biotechnology-based 
sector (Foundation For Research Science and Technology, 2000, p. 1).” 
 
The document goes on to describe “principles and behaviours to be encouraged” which 
include: the need for a targeted, rapid and flexible investment system by Government; the 
development of an entrepreneurial spirit; partnerships and linkages between stakeholders; 
increased global linkages to exploit New Zealand’s competitive advantage; and enhanced 
integration and leadership among sector groups and along value chains. 
 
New Zealand’s approach has contrasted strongly with some of its regional trading partners. In 
Australia, the federal government established two new agencies “to ensure Australia realises 
the potential gains being offered by biotechnology” (Biotechnology Australia, 2000). The 
Singapore Government has a strategy ‘to position Singapore as the strategic hub for the 
pharmaceutical, biotechnology and health care industry in Asia’ while Taiwan aims to develop 
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into ‘an Asia-Pacific R&D Center’ and ‘an Asia-Pacific Manufacturing Center for high-tech 
products’. Taiwan currently spends NZ$200 million per year on biotech and is increasing its 
technology budget by 10-15% per year (Rolleston, 1999, p. 43).  
 
There is a significant level of dissatisfaction with government policy towards research, science 
and technology in New Zealand. Indeed Sommer (2001, p. 7) found that the 1996 and 2000 
surveys of New Zealand scientists and technologists “indicate a stunning level of dissonance 
over New Zealand science and technology policy reforms”.  The statement “The management 
systems now in place are appropriate for the effective advancement of research,” evoked 
69.8% disagreement in 1996 and 70.9% in 2000. Similarly, the statement “The changes in the 
organization of New Zealand science over the past four years have enhanced my 
situation/conditions for performing innovative research,” was disagreed with by 70% of 
panellists in 2000. 
 
More specific criticisms are that “the science reforms produced an over-emphasis on 
incremental innovation or technology and undermined the science base, leaving less time for 
research from which big new ideas could emerge” (quoted in Mazoyer, 1999, p. 9); and a 
“focus on small projects focussed on individuals has taken away the ability of CRI’s to build 
future science capabilities”(interview A). This is supported by Petersen (1998, p. 10) who 
suggests “there must be some mechanism that allows scientist to be kept on the payroll while 
alternative funding routes are worked out”. There is a serious brain drain of students 
completing PhD’s “because they are not prepared to spend the rest of their lives living from 
hand to mouth on short-term contracts”. 
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On a more positive note some interviewees found that government programmes to encourage 
technology transfer were useful. They attributed low uptake of these programmes to company 
culture and short termism. Others said accountability requirements were excessive (Mazoyer, 
1999, p. 10). 
 
R&D Funding 
It has been known for some years that New Zealand’s expenditure on R&D is low relative to 
other OECD members. In 1996 New Zealand’s gross expenditure on R&D (GERD) was 
0.98% compared to 2% or over for G7 and a group of small OECD countries (Engelbrecht 
and Darroch, 1999). Spending by New Zealand industry, as a % of GDP was 0.26% in 1995, 
far below the OECD average of 1.46% (OECD, 1999, p. 131). While no comprehensive data 
is available on R&D expenditure on biotechnology, it may be logical to assume that “if New 
Zealand is bad at doing R&D generally it would  [expect to be] a whole lot worse in the 
biotech area” (interview B). 
 
One factor that would be expected to affect the level of R&D expenditure by industry is the tax 
and incentive regime. In a recent review of the evidence on the effects of fiscal incentives for 
R&D, Hall and Van Reenen (2000, p. 449) concluded that “in the current (imperfect) state of 
knowledge … a dollar in tax credit for R&D stimulates a dollar of additional R&D”.  
 
All OECD countries except New Zealand have special tax schemes for R&D expenditures 
such as immediate write-off and various types of tax credit, indeed New Zealand came bottom 
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of an OECD league table of the amount of tax subsidy for R&D (OECD, 1999, p. 135). In 
New Zealand, private sector expenditure of one dollar cost companies $1.13 after tax and 
compliance were included. This compared to 89 cents in Australia, 83 cents in Canada and 69 
cents in Spain.  
 
It has also been suggested that differences in national tax regimes may significantly bias 
reported levels of R&D expenditure. The negative treatment of such expenditures in New 
Zealand encourages under-reporting while the favourable treatment in other countries 
encourages widespread over-reporting. 
Industry views appear to be somewhat polarised on whether the tax treatment of R&D 
spending has had a major effect on the level of expenditure in the private sector. Some large 
players saw this as a key influence: “the 150% tax rebate meant that you could do research for 
free in Australia and make money out of it … it was a pretty favourable regime – nothing like 
that here” (interview B). Others were more sceptical: “I have not seen results that suggest 
support of R&D delivers real commercial benefits” (interview C). 
 
Difficulties in obtaining venture capital may also constrain start-up or expanding biotech firms in 
New Zealand, although some suggest “the lack of entrepreneurs who can build companies, 
rather than a shortage of money, is curtailing the development of new companies” (Springall, 
2000). Until recently no venture capital appeared to be available for biotechnology and 
companies relied on traditional methods of funding. However there has recently been a marked 
increase in private sector funding. At a 1999 venture capital conference in Auckland one 
speaker concluded “New Zealand does not yet have a venture capital market. But we do have 
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up to NZ$800 million in venture capital available for high-tech firms and another NZ$900 
million already committed by 30 venture capital companies (Caragata, 2000)”. Overall venture 
capital investment in Australia and New Zealand combined has increased sharply over the last 
three years with the health/bioscience category showing a huge increase from A$7.9 million in 
1998 to A$81 million in 1999 (Australian Venture Capital Journal, 2000).   
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4.  Conclusions 
 
New Zealand has some ‘islands of excellence’ where world-leading biotechnology R&D is 
carried out and despite its small size has played a significant role in the biotechnology 
revolution. While most biotech activities build on existing strengths in primary industry (e.g. 
forestry, deer and sheep) there are also examples of innovative research in health and the 
creation of intellectual property. The modern biotechnology ‘sector’ is small; consisting of 
around 60 organisations employing approximately 1700 people, receiving biotech income of 
NZ$236 million. A further 36 enterprises use modern biotech processes and employ around 
950 people in ‘biotech based activities’, which provide income of NZ$112 million. New 
Zealand’s rate of modern biotech patent applications is below average for the G7 and for a 
reference group of small developed OECD economies. New Zealand’s biotech revenue per 
million population (NZ$54 million) is rather lower than Canada's (NZ$94 million), but the 
difference is fairly small considering Canada’s higher per capita income and proximity to the 
United States. 
 
The factors that seem to have encouraged the emergence of world-leading research are diverse 
ranging from strong basic science in medical research and science push in sheep genomics, to 
industry pull in the case of forest biotechnology. Growth in these and other biotech-based 
sectors may be constrained by the poor performance of New Zealand’s National System of 
Innovation. The system is dominated by Crown Research Institutes and universities which rely 
on government for the majority of their funding. Leading edge work is carried out in certain 
areas, but this tends to involve links with a small number of organisations rather than strong 
connections to any wider system of innovation. There have been major changes to research, 
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science and technology policy since the late 80’s, but it remains to be seen whether these will 
result in improved performance.  
 
The New Zealand Government has not taken leadership in fostering innovation in modern 
biotechnology. Indeed government and industry only seem to have taken a close interest in 
biotechnology in the last four to five years.  New Zealand has not made the kinds of large 
investment seen in Australia and some of its regional trading partners. Instead it has 
concentrated on science sector reforms and a free market oriented approach. New Zealand 
has the potential to demonstrate a new model for the development of a biotech industry based 
on comparative advantage in primary industry and some other niche areas. The jury is still out 
on whether New Zealand’s innovation environment will allow that potential to be achieved. 
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Tables and Figures 
 
Figure 1: Classification of Biotech Respondents 
 
 
 
Industrial Group No. of  
Enterprises 
No. of Biotech 
Employees 
Biotech 
Income 
(NZ$ millions) 
Primary Products and 
Manufacturing 
15 214 106 
Scientific Research  24 540 83 
Tertiary Education 6 625 c 
Health Services and Other 9 288 c 
Total for Modern Biotech 
Enterprises 
57 1,667 236 
Modern Biotech Users 36 944 112 
Note: Data in cells marked c are not presented and count data are subject to random 
rounding to base three in order to meet the confidentiality provisions of the Statistics Act 
1975.  
 
Table 1: Key Characteristics of Modern Biotech Enterprises 
 
 
 Canada  
1999 
Australia 
1998/99 
NZ 
1998/99 
Population (1997) 30.3 18.5 3.8 
No. of biotech enterprises 358 120 39 
Total biotech revenue1 (NZ$ m) 2850 1077 205 
Biotech revenue per million population (NZ$ m) 94 58 54 
Revenue per firm (NZ$ m) 8.0 9.0 5.3 
Biotech related employees (Headcount) 7695 3801 1708 
Biotech related employees per million population 254 205 449 
% of products and processes in R&D stage 49% 47% 72% 
Data for Canada is extracted from McNiven (2001) 
 
 
 Modern   !!!!! Traditional 
Modern Biotech 
Enterprises  
(MBEs) 
Traditional Biotech 
Enterprises 
(TBEs) 
Creators 
$ 
$ 
$ 
$ 
Users 
Modern Biotech 
 Users 
(MBUs) 
Traditional Biotech 
Users 
(TBUs) 
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Table 2: Comparison of Biotech in New Zealand, Canada and Australia 
 PCT Patent Applications 
(1 Jan 1997 – 15 May, 2000) per million population 
 
 C12N 
Modern Biotechnology 
Broad 
Definition 
All 18 Countries 13.8 22.5 
G7 13.6 22.2 
Small Countries2 15.4 25.7 
Australia 12.1 19.1 
New Zealand 8.0 15.7 
 
 
Table 3: New Zealand and OECD Patenting Rates in Biotechnology 
 
 
1 Based on an exchange rate of NZ$1.5= C$1 
2 Austria, Belgium, Denmark, Finland, Ireland, Netherlands, NZ, Norway, Sweden, Switzerland. 
